These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 32887121)

  • 21. Positron emission tomography imaging in evaluation of MS pathology in vivo.
    Högel H; Rissanen E; Vuorimaa A; Airas L
    Mult Scler; 2018 Oct; 24(11):1399-1412. PubMed ID: 30091657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain.
    Horti AG; Villemagne VL
    Curr Pharm Des; 2006; 12(30):3877-900. PubMed ID: 17073685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
    Zhang F; Xue J; Shao J; Jia L
    Drug Discov Today; 2012 May; 17(9-10):475-85. PubMed ID: 22210121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status of positron emission tomography radiotracers for serotonin receptors in humans.
    Zimmer L; Le Bars D
    J Labelled Comp Radiopharm; 2013; 56(3-4):105-13. PubMed ID: 24285316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioligands for the dopamine receptor subtypes.
    Prante O; Maschauer S; Banerjee A
    J Labelled Comp Radiopharm; 2013; 56(3-4):130-48. PubMed ID: 24285319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioligand development for molecular imaging of the central nervous system with positron emission tomography.
    Honer M; Gobbi L; Martarello L; Comley RA
    Drug Discov Today; 2014 Dec; 19(12):1936-44. PubMed ID: 25173703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review.
    Lambrinidis G; Vallianatou T; Tsantili-Kakoulidou A
    Adv Drug Deliv Rev; 2015 Jun; 86():27-45. PubMed ID: 25819487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography: ligand imaging.
    Moghbel M; Newberg A; Alavi A
    Handb Clin Neurol; 2016; 135():229-240. PubMed ID: 27432668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor.
    Spinelli F; Mu L; Ametamey SM
    J Labelled Comp Radiopharm; 2018 Mar; 61(3):299-308. PubMed ID: 29110331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficiency gains in tracer identification for nuclear imaging: can in vivo LC-MS/MS evaluation of small molecules screen for successful PET tracers?
    Joshi EM; Need A; Schaus J; Chen Z; Benesh D; Mitch C; Morton S; Raub TJ; Phebus L; Barth V
    ACS Chem Neurosci; 2014 Dec; 5(12):1154-63. PubMed ID: 25247893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain radioligands--state of the art and new trends.
    Halldin C; Gulyás B; Langer O; Farde L
    Q J Nucl Med; 2001 Jun; 45(2):139-52. PubMed ID: 11476163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
    Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31905752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positron emission tomography (PET) methodology for small animals and its application in radiopharmaceutical preclinical investigation.
    Hume SP; Jones T
    Nucl Med Biol; 1998 Nov; 25(8):729-32. PubMed ID: 9863557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Strategy for development of imaging biomarkers].
    Ishiwata K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):67-71. PubMed ID: 19562944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New developments of dopaminergic imaging in Parkinson's disease.
    Varrone A; Halldin C
    Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):68-82. PubMed ID: 22460161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Trends and Current Status of Positron-Emission Tomography and Single-Photon-Emission Computerized Tomography Radioligands for Neuronal Serotonin Receptors and Serotonin Transporter.
    Hazari PP; Pandey A; Chaturvedi S; Mishra AK
    Bioconjug Chem; 2017 Nov; 28(11):2647-2672. PubMed ID: 28767225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
    Shiue CY; Welch MJ
    Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?
    Vallabhajosula S; Solnes L; Vallabhajosula B
    Semin Nucl Med; 2011 Jul; 41(4):246-64. PubMed ID: 21624560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.